<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859781</url>
  </required_header>
  <id_info>
    <org_study_id>0810010067</org_study_id>
    <secondary_id>J591+Ketoconazole</secondary_id>
    <nct_id>NCT00859781</nct_id>
  </id_info>
  <brief_title>177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer</brief_title>
  <official_title>A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591&#xD;
      in combination with ketoconazole and hydrocortisone against prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research is being done because the standard treatments for prostate cancer that has&#xD;
      returned (PSA is elevated) after surgery and/or radiation and progressed on initial hormonal&#xD;
      therapy are not curative. Existing treatments, such as the ketoconazole used as part of this&#xD;
      study may decrease PSA temporarily, but unfortunately the cancer continues to grow. This&#xD;
      experimental drug is designed to seek out all of the prostate cancer cells and to deliver a&#xD;
      lethal dose of radiation to the areas of cancer, but not to normal areas. Some of the normal&#xD;
      organs (liver, kidney and bone marrow) do receive some radiation dose that is within the&#xD;
      acceptable limits.&#xD;
&#xD;
      The experimental drug in this study includes an antibody (abbreviated: mAb) called &quot;J591&quot;. It&#xD;
      is a protein molecule which can bind to a specific site on a prostate cancer cell. A very&#xD;
      energetic radioactive (an unstable atom) metal called 177Lutetium (abbreviated: 177Lu) is&#xD;
      attached to the J591 antibody. The fully assembled drug is called &quot;177Lu-J591&quot;. The study&#xD;
      will assess the potential of the energy given off by the radioactive compound to kill cancer&#xD;
      cell. This study may also involve the use of 111Indium (abbreviated 111In). This is also an&#xD;
      energetic radioactive particle, but does not generally give off enough energy to kill cancer&#xD;
      cells, but allows researchers to take pictures. This radioactive particle is also attached to&#xD;
      the J591 antibody (called 111In-J591) and will serve as a placebo (treatment with no active&#xD;
      medicine).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2009</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the number of subjects with Proportion free of radiographically evident metastases</measure>
    <time_frame>18 months after study drug administration</time_frame>
    <description>Subjects will perform a CT and/or MRI scan of the abdomen and pelvis, chest x-ray or CT scan of the chest and bone scan to determine proportion free of radiographically evident metastases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PSA response rate</measure>
    <time_frame>Collected at screening, V2, V3, V5, V9 then every 4 weeks till PSA progression or end of study at approximately 100 months</time_frame>
    <description>PSA response will be determined by comparing the PSA levels after therapy to the baseline and pre-treatment PSA via blood speciemens</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1. 177Lu-J591+Ketoconzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 177Lu-J591 Infusion, continue ketoconazole and hydrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. 111In-J591 + ketoconazole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 111In-J591 (placebo) Infusion, continue ketoconazole and hydrocortisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment</description>
    <arm_group_label>1. 177Lu-J591+Ketoconzole</arm_group_label>
    <other_name>J591</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)</description>
    <arm_group_label>1. 177Lu-J591+Ketoconzole</arm_group_label>
    <arm_group_label>2. 111In-J591 + ketoconazole</arm_group_label>
    <other_name>Nizoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)</description>
    <arm_group_label>1. 177Lu-J591+Ketoconzole</arm_group_label>
    <arm_group_label>2. 111In-J591 + ketoconazole</arm_group_label>
    <other_name>Cortef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>111In-J591</intervention_name>
    <description>111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment</description>
    <arm_group_label>2. 111In-J591 + ketoconazole</arm_group_label>
    <other_name>J591</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate previously&#xD;
             treated with surgery and/or radiotherapy.&#xD;
&#xD;
          -  Biochemical progression (rising PSA) after medical or surgical castration&#xD;
&#xD;
          -  High risk of systemic progression defined as:&#xD;
&#xD;
               1. Rising PSA as defined above and either:&#xD;
&#xD;
               2. Absolute PSA &gt; 20 ng/mL AND/OR&#xD;
&#xD;
               3. PSA doubling time &lt; 8 months&#xD;
&#xD;
          -  No evidence of local recurrence or distant metastases&#xD;
&#xD;
          -  Age &gt;18 years.&#xD;
&#xD;
          -  Serum testosterone &lt; 50 ng/ml&#xD;
&#xD;
          -  Patients capable of fathering children must agree to use an effective method of&#xD;
             contraception for the duration of the trial.&#xD;
&#xD;
          -  Subjects on bisphosphonate therapy must be on a stable dose and must have started&#xD;
             therapy &gt; 4 weeks prior to protocol therapy.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of red blood cell or platelet transfusions within 4 weeks of treatment&#xD;
&#xD;
          -  Use of hematopoietic growth factors within 4 weeks of treatment&#xD;
&#xD;
          -  Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment&#xD;
&#xD;
          -  Prior radiation therapy encompassing &gt;25% of skeleton (see Appendix C)&#xD;
&#xD;
          -  Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®,&#xD;
             Quadramet®)&#xD;
&#xD;
          -  Platelet count &lt;150,000/mm3 or known primary qualitative platelet disorder&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt;2,000/mm3&#xD;
&#xD;
          -  Hematocrit &lt;30 percent and Hemoglobin &lt; 10 g/dL&#xD;
&#xD;
          -  Abnormal coagulation profile (PT or INR, PTT &gt; 1.3x ULN) unless on therapeutic&#xD;
             anticoagulation - see concomitant meds section&#xD;
&#xD;
          -  Serum creatinine &gt;2.5 mg/dL&#xD;
&#xD;
          -  AST (SGOT) &gt;2x ULN&#xD;
&#xD;
          -  Bilirubin (total) &gt;1.5x ULN; subjects with Gilbert's syndrome will be allowed if&#xD;
             direct bilirubin is within institutional normal limits&#xD;
&#xD;
          -  Active serious infection&#xD;
&#xD;
          -  Active angina pectoris or NY Heart Association Class III-IV&#xD;
&#xD;
          -  ECOG Performance Status &gt; 2&#xD;
&#xD;
          -  Life expectancy &lt;12 months&#xD;
&#xD;
          -  History of deep vein thrombosis and/or pulmonary embolus within 1 month of study entry&#xD;
&#xD;
          -  Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or&#xD;
             hematological organ systems which might preclude completion of this study or interfere&#xD;
             with determination of causality of any adverse effects experienced in this study&#xD;
&#xD;
          -  Prior investigational therapy (medications or devices) within 4 weeks of treatment.&#xD;
             Furthermore, other investigational therapy is not permitted during the treatment&#xD;
             phase.&#xD;
&#xD;
          -  Prior use of ketoconazole for the purposes of prostate cancer therapy for greater than&#xD;
             1 month&#xD;
&#xD;
          -  Known history of HIV. The effects of J591 are unknown in this population. Furthermore,&#xD;
             ketoconazole has many well-described drug-drug interactions which could affect&#xD;
             antiviral therapy. If necessary, this population will be studied separately.&#xD;
&#xD;
          -  Currently active other malignancy other than non-melanoma skin cancer. Patients are&#xD;
             considered not to have &quot;currently active&quot; malignancy if they have completed any&#xD;
             necessary therapy and are considered by their physician to be at less than 30% risk of&#xD;
             relapse.&#xD;
&#xD;
             - Known history of known myelodysplastic syndrome&#xD;
&#xD;
          -  Adrenal hormone inhibitors (other than ketoconazole) within 4 weeks prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  Finasteride (Propecia® or Proscar®) or dutasteride (Avodart®) within 4 weeks of&#xD;
             enrollment&#xD;
&#xD;
          -  Patients on corticosteroids prior to enrollment must have either discontinued and&#xD;
             shown biochemical progression or have biochemical progression on a stable dose&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott T Tagawa, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GUONC Research Team</last_name>
    <email>guonc@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive cancer center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Alarcon</last_name>
      <phone>202-687-7607</phone>
      <email>sva24@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>George K Philips, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida, Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marietta Moore</last_name>
      <email>marlmoore@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Nabil Adra, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Zehr, RN, MA</last_name>
      <phone>319-353-8914</phone>
      <email>pamela-zehr@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Vaena, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUONC Research Team</last_name>
      <email>guonc@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Scott T Tagawa, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Grzejka, RN,BSN</last_name>
      <phone>412-623-4891</phone>
      <email>grzejkac@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brieana Rowles, MA</last_name>
      <phone>(412) 647-8258</phone>
      <email>rowlesbm@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Leonard Appleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

